NCT06253000 Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium
| NCT ID | NCT06253000 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bakulev Scientific Center of Cardiovascular Surgery |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 158 participants |
| Start Date | 2023-06-10 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 158 participants in total. It began in 2023-06-10 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Atrial fibrillation (AF) is the cause of 20% of strokes, and the risk of stroke in a person suffering from this arrhythmia increases by 5 times. Ischemic stroke in patients with AF is often fatal and, compared with stroke of other etiology, leads to the most pronounced disability and more often recurs. Accordingly, the risk of death in patients with AF-related stroke is 2 times higher, and treatment costs increase 1.5 times. The main interventional method of treating AF, available in most medical institutions, is the use of radio frequency and/or cryoenergy to eliminate destructive damage to the left atrium (LA). The aim of this study is to compare two different interventional methods and identify predictors of recurrence in patients with persistent and long-term AF.
Eligibility Criteria
Inclusion Criteria: * Age over 18 years old; * Atrial fibrillation resistant to antiarrhythmic therapy; * Persistent and long-persisting form of atrial fibrillation; * The patient's consent to participate in the study. Exclusion Criteria: * Age under 18 and over 80 years old; * The presence of another cardiac pathology requiring surgical treatment; * Congenital heart defects; * Previous "open" cardiac surgery; * Bone marrow diseases; * Pathology of the blood coagulation system; * The left ventricular ejection fraction is less than 40%; * Moderate to severe renal insufficiency (creatinine clearance \<50 ml/min); * Drug-resistant hypertension (despite hypotensive therapy); * Organically altered mitral valve; * There are reasons to assume that the patient will not show up for subsequent visits (control points of the study) for various reasons; * The patient's participation in another clinical trial.
Contact & Investigator
Andrey Filatov
PRINCIPAL INVESTIGATOR
Bakulev Scientific Center for Cardiovascular Surgery
Frequently Asked Questions
Who can join the NCT06253000 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06253000 currently recruiting?
Yes, NCT06253000 is actively recruiting participants. Contact the research team at agfilatov@bakulev.ru for enrollment information.
Where is the NCT06253000 trial being conducted?
This trial is being conducted at Moscow, Russia.
Who is sponsoring the NCT06253000 clinical trial?
NCT06253000 is sponsored by Bakulev Scientific Center of Cardiovascular Surgery. The principal investigator is Andrey Filatov at Bakulev Scientific Center for Cardiovascular Surgery. The trial plans to enroll 158 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.